

David A. Schreier

Department of Biomedical Engineering,
University of Wisconsin,
2146 ECB, 1550 Engineering Drive,
Madison, WI 53706

Omid Forouzan

Department of Biomedical Engineering,
University of Wisconsin,
2146 ECB, 1550 Engineering Drive,
Madison, WI 53706

Timothy A. Hacker

Department of Medicine,
1685 Highland Avenue,
5158 Medical Foundation Centennial Building,
Madison, WI 53705-2281

John Sheehan

Department of Medicine,
1685 Highland Avenue,
5158 Medical Foundation Centennial Building,
Madison, WI 53705-2281

Naomi Chesler¹

Department of Biomedical Engineering,
University of Wisconsin,
2146 ECB, 1550 Engineering Drive,
Madison, WI 53706;
Department of Medicine,
1685 Highland Avenue,
5158 Medical Foundation Centennial Building,
Madison, WI 53705-2281
e-mail: chesler@enr.wisc.edu

Increased Red Blood Cell Stiffness Increases Pulmonary Vascular Resistance and Pulmonary Arterial Pressure

*Patients with sickle cell anemia (SCD) and pulmonary hypertension (PH) have a significantly increased risk of sudden death compared to patients with SCD alone. Sickled red blood cells (RBCs) are stiffer, more dense, more frequently undergo hemolysis, and have a sixfold shorter lifespan compared to normal RBCs. Here, we sought to investigate the impact of increased RBC stiffness, independent of other SCD-related biological and mechanical RBC abnormalities, on the hemodynamic changes that ultimately cause PH and increase mortality in SCD. To do so, pulmonary vascular impedance (PVZ) measures were recorded in control C57BL6 mice before and after ~50 μ l of blood (Hct=45%) was extracted and replaced with an equal volume of blood containing either untreated RBCs or RBCs chemically stiffened with glutaraldehyde (Hct=45%). Chemically stiffened RBCs increased mean pulmonary artery pressure (mPAP) (13.5 \pm 0.6 mmHg at baseline to 23.2 \pm 0.7 mmHg after the third injection), pulmonary vascular resistance (PVR) (1.23 \pm 0.11 mmHg*min/ml at baseline to 2.24 \pm 0.14 mmHg*min/ml after the third injection), and wave reflections (0.31 \pm 0.02 at baseline to 0.43 \pm 0.03 after the third injection). Chemically stiffened RBCs also decreased cardiac output, but did not change hematocrit, blood viscosity, pulmonary arterial compliance, or heart rate. The main finding of this study is that increased RBC stiffness alone affects pulmonary pulsatile hemodynamics, which suggests that RBC stiffness plays an important role in the development of PH in patients with SCD. [DOI: 10.1115/1.4032187]*

Keywords: cardiopulmonary hemodynamics, sickle cell anemia, pulmonary vascular impedance, red blood cell stiffness, pulmonary hypertension

Introduction

SCD is one of the most common heritable monogenetic diseases in the world. The World Health Organization estimates are ~275,000 births per year worldwide with SCD [1]. SCD is characterized by a single amino acid substitution of hydrophobic valine for hydrophilic glutamic acid in the β -chain of hemoglobin. This substitution modifies the quaternary structure of the protein, predisposing it to polymerization of hemoglobin in the deoxygenated state which deforms the RBC into the characteristic sickled shape [2,3]. Sickled RBCs are biologically and mechanically quite different from normal RBCs, and these differences lead to clinically important consequences. For example, clinically, SCD is associated with ischemia, thrombotic events, oxidative stress, and reperfusion injury in multiple organs [4]. Biologically, sickled RBCs have significantly shortened lifespan and more frequently undergo intravascular hemolysis, which releases free hemoglobin into the plasma, and in turn scavenges nitric oxide [5]. The scavenging of nitric oxide can acutely impair vasodilation and chronically cause endothelial cell dysfunction, vascular cell proliferation, and inflammatory stress [4]. Mechanically, sickled RBCs have increased stiffness [6], which leads to trapping in the microcirculation and downstream ischemia. All of these consequences of SCD can and often do have significant effects on the vasculature including increasing PVR [4] and systemic arterial wave reflections [7].

The World Health Organization has found that of the chronic cardiopulmonary effects of SCD, PH is the major cause of morbidity and mortality [4]. In fact, patients with SCD-related PH have a substantially increased risk of sudden death compared to those with SCD alone, as high as a 50% within 2 yr [8,9]. SCD is associated with a high prevalence of PH—about 30% [10,11]. Higher still is the percentage of SCD patients with evidence of PH via lung histology at the time of death—75% [12]. While mortality in patients with SCD-related PH is high, right heart catheterization studies have shown only moderate increases in mPAP (30–40 mmHg with SCD compared to 15–20 mmHg in healthy adults [13]) and PVR (2.24 Wood units with SCD compared to 1 Wood unit in healthy adults [13]). Additionally, patients with SCD-related PH have shown little to no improvement with therapies for PH alone [14–16].

Therefore, mild PH in patients with SCD, which does not respond to traditional therapies, dramatically increases mortality via mechanisms that are not well understood. The mechanical changes in RBCs with SCD are a likely contributor to abnormal pulmonary vascular hemodynamics. Mechanical changes in RBCs are particularly significant in the low oxygen pulmonary arterial vasculature as RBCs are most likely to sickle in this decreased oxygen environment. How mechanical changes to RBCs in SCD, such as increased stiffness, has been shown to affect myocardial infarction, essential hypertension, and modify whole blood viscosity [17,18], affect right ventricular (RV) afterload has yet to be investigated.

In this study, we sought to investigate the impact of increased RBC stiffness, independent of other SCD-related biological and

¹Corresponding author.

Manuscript received August 3, 2015; final manuscript received November 30, 2015; published online January 27, 2016. Editor: Victor H. Barocas.

mechanical RBC abnormalities, on the hemodynamic changes that ultimately cause PH and increase mortality in SCD. We hypothesized that SCDlike RBC rigidity would increase mPAP, PVR, and wave reflections in the pulmonary circulation of otherwise healthy lungs. To test this hypothesis, we replaced normal RBCs with chemically stiffened RBCs in mice and measured PVZ in vivo. PVZ is the most comprehensive measure of RV afterload, since it measures opposition to both steady and oscillatory flow in the pulmonary vasculature. Our results confirmed that RBC stiffness dramatically increases mPAP, PVR, and wave reflections, and likely contributes to poor outcomes in the SCD-related PH.

Materials and Methods

Mice. Male C57BL6/J mice, 12–14 weeks old, were obtained from Jackson Laboratory (Bar Harbor, ME) and used either as donors for RBCs or for in vivo experiments. Mice used for in vivo experiments were divided into two separate groups: one injected with control (CTL), untreated RBCs ($n = 6$) and the other injected with chemically stiffened RBCs ($n = 11$). The University of Wisconsin Institutional Animal Care and Use Committee approved all procedures.

RBC Preparation. Whole blood was drawn from donor mice and centrifuged at 500 g for 15 min. Then, the plasma, buffy coat, and top layer of cells were removed. RBCs were resuspended to an Hct of ~45% with osmolality and PH-balanced saline and centrifuged three more times to remove all non-RBC components. To create SCD-like rigidity, RBCs were treated with 0.016% glutaraldehyde for 30 min, which has been shown to stiffen RBCs without altering cell shape [19]. Chemically stiffened RBCs were centrifuged at 500 g for 15 min eight times with isotonic saline and then were resuspended to 45% Hct with isotonic buffered saline.

In Vivo Hemodynamic Measurements

Mice were instrumented for PVZ measurements as previously described [20,21]. In brief, mice were anesthetized with urethane (2 mg/g body weight), intubated and placed on a ventilator using a tidal volume of ~225 μ l and respiratory rate of ~200 breaths/min of room air. A 1.2F catheter-tip pressure transducer (Scisense, Inc., London, ON, Canada) was inserted into the right carotid

artery to monitor systemic arterial pressures and a 1.0F pressure-tip catheter (Millar Instruments, Houston, TX) was inserted into main pulmonary artery through the right ventricle to measure pulmonary arterial pressures. Pressure tracings were recorded at 5 kHz on a custom hemodynamic workstation (Cardiovascular Engineering, Norwood, MA). Measurement of blood flow velocity and main PA inner diameter were performed via ultrasound (Visualsonics, Toronto, ON, Canada) with a 40 MHz probe during the surgery and recorded with our custom system as done previously; volumetric flow rate (Q) was calculated using velocity time integral and main PA inner diameter measurements obtained via long axis view [20,21].

After all measurements were completed at baseline, ~50 μ l of blood was extracted and replaced with an equal volume of saline containing chemically stiffened RBCs or control RBCs at 45% by volume (Hct = 45%). After a 5-min stabilization period, all hemodynamic measurements were repeated, and this cycle was repeated two more times, for three total blood replacements and four total PVZ measurements. Hematocrit was measured with each 50 μ l blood collection. Before euthanasia, a 500 μ l sample of blood was taken for viscosity analysis. Each sample was drawn into a closed tube for oscillatory tube viscometry (Vilastic-3 Viscoelasticity Analyzer). Samples were sheared with a constant 2 Hz frequency and continually increasing shear rate. The viscometer was calibrated before testing the first sample of the day; at most four samples were tested per day and the duration of testing each sample was 25 min. Measurements were performed within 12 hrs of collection.

In vivo experiments with chemically stiffened RBCs and control RBCs were performed by different small animal surgeons trained by one of the authors (TAH).

In Vivo Hemodynamic Calculations

Data obtained during our experiments were analyzed as previously described [20,21] using our custom software and hemodynamic workstation (Cardiovascular Engineering, Norwood, MA). In brief, our software used electrocardiogram as a fixed standard of reference for the Q and P waveforms, which then processed and analyzed our data accordingly. All equations used henceforth can be found in these previous publications [20,21], including but not limited to PVR Z_0 , characteristic impedance Z_C , pulmonary arterial compliance Ca , wave reflections RQ , and pulse wave velocity (PWV).

Table 1 Body weight, hematocrit, and hemodynamic measurements from PVZ in mice that underwent blood replacement with chemically stiffened RBCs

Stiff RBCs	Baseline	First	Second	Third
Body weight (g)	26.8 \pm 0.6	N/A	N/A	N/A
Hct	42.8 \pm 1.2	42.7 \pm 1.1	42.4 \pm 1.7	42.1 \pm 1.5
sAP (mmHg)	77 \pm 4	75 \pm 5	72 \pm 6	73 \pm 3
mPAP (mmHg)	13.5 \pm 0.6	18.9 \pm 0.4 ^a	21.8 \pm 0.5 ^{a,b}	23.2 \pm 0.7 ^{a,b}
sPAP (mmHg)	20.0 \pm 0.3	25.1 \pm 0.6 ^a	28.4 \pm 0.4 ^{a,b}	29.7 \pm 0.7 ^{a,b}
dPAP (mmHg)	7.9 \pm 0.7	13.4 \pm 0.5 ^a	16.4 \pm 0.3 ^{a,b}	18.1 \pm 0.6 ^{a,b}
PVR (mmHg min/ml)	1.23 \pm 0.11	1.85 \pm 0.16 ^a	2.22 \pm 0.18 ^{a,b}	2.24 \pm 0.14 ^{a,b}
RQ	0.31 \pm 0.02	0.39 \pm 0.02 ^a	0.44 \pm 0.01 ^{a,b}	0.43 \pm 0.03 ^a
Ca (mm ² /mmHg)	1.40 \pm 0.08	1.36 \pm 0.16	1.28 \pm 0.13	1.23 \pm 0.14
CO (ml/min)	12.0 \pm 0.7	10.7 \pm 0.6 ^a	10.1 \pm 0.6 ^a	9.6 \pm 0.8 ^a
Z_C (mmHg min/ml)	0.26 \pm 0.02	0.22 \pm 0.01	0.19 \pm 0.01 ^a	0.19 \pm 0.01 ^a
Tes (ms)	52.0 \pm 1.0	47.5 \pm 0.5 ^a	46.4 \pm 0.8 ^a	45.4 \pm 1.8 ^a
PWV (mm/ms)	0.34 \pm 0.03	0.31 \pm 0.02	0.29 \pm 0.05	0.29 \pm 0.03
HR	551 \pm 12	549 \pm 9	541 \pm 9	530 \pm 5
PA diameter (mm)	1.37 \pm 0.06	1.39 \pm 0.08	1.40 \pm 0.07	1.43 \pm 0.04
PP (mmHg)	12.3 \pm 0.6	12.0 \pm 0.5	12.2 \pm 0.8	11.4 \pm 0.9

Note: Values are means \pm SE; $n = 11$ baseline, first, second, and third blood replacements. PA, pulmonary arterial; HCT, hematocrit; sAP, systolic aortic pressure; mPAP, mean PA pressure; sPAP, systolic PA pressure; dPAP, diastolic PA pressure; PVR, pulmonary vascular resistance; RQ, PA wave reflections; Ca, PA compliance; CO, cardiac output; Z_C , characteristic impedance; Tes, duration of systole; PWV, pulse wave velocity; HR, heart rate; PP, pulse pressure.

^a $P < 0.05$ versus CTL.

^b $P < 0.05$ versus first blood replacement.

Table 2 Body weight, hematocrit, and hemodynamic measurements from PVZ in mice that underwent blood replacement with control RBCs

Ctl RBCs	Baseline	First	Second	Third
Body weight (g)	26.5 ± 0.9	N/A	N/A	N/A
Hct	41.4 ± 1.4	41.7 ± 1.6	40.8 ± 1.9	41.2 ± 1.3
sAP (mmHg)	67 ± 2	66 ± 4	70 ± 8	63 ± 5
mPAP (mmHg)	15.9 ± 1.0	16.0 ± 1.3	15.8 ± 1.4	15.2 ± 1.8
sPAP (mmHg)	22.3 ± 1.0	22.5 ± 1.4	22.3 ± 1.5	21.5 ± 2.0
dPAP (mmHg)	10.7 ± 0.8	10.8 ± 1.1	10.3 ± 1.2	10.0 ± 1.6
PVR (mmHg min/ml)	2.0 ± 0.3	2.0 ± 0.4	1.9 ± 0.3	1.7 ± 0.3
RQ	0.35 ± 0.02	0.32 ± 0.02	0.34 ± 0.02	0.32 ± 0.01
Ca (mm ² /mmHg)	1.34 ± 0.16	1.40 ± 0.23	1.41 ± 0.24	1.37 ± 0.28
CO (ml/min)	8.6 ± 0.5	8.8 ± 0.6	8.9 ± 0.7	8.7 ± 0.2
Z _C (mmHg min/ml)	0.28 ± 0.02	0.30 ± 0.02	0.28 ± 0.02	0.26 ± 0.03
Tes (ms)	47.8 ± 1.1	48.0 ± 1.2	49.2 ± 1.8	49.0 ± 1.9
PWV (mm/ms)	0.35 ± 0.02	0.37 ± 0.02	0.36 ± 0.03	0.35 ± 0.04
HR	527 ± 25	507 ± 28	492 ± 30 ^a	521 ± 20
PA diameter (mm)	1.30 ± 0.03	1.30 ± 0.02	1.31 ± 0.02	1.32 ± 0.02
PP (mmHg)	11.8 ± 0.5	11.8 ± 0.6	12.2 ± 0.4	12.0 ± 0.6

Note: Values are means ± SE; *n* = 6 baseline, first, second, and third blood replacements. PA, pulmonary arterial; HCT, hematocrit; sAP, systolic aortic pressure; mPAP, mean PA pressure; sPAP, systolic PA pressure; dPAP, diastolic PA pressure; PVR, pulmonary vascular resistance; RQ, PA wave reflections; Ca, PA compliance; CO, cardiac output; Z_C, characteristic impedance; Tes, duration of systole; PWV, pulse wave velocity; HR, heart rate; PP, pulse pressure.

^a*P* < 0.05 versus CTL.

Statistical Analysis

For each group, the significances of the overall changes in parameters with blood replacement were assessed using a one-way analysis of variance (ANOVA) for condition (chemically stiffened or control RBCs) or generalized least squares for

repeated measurements (with subsequent blood replacements). Due to the different surgical personnel and consequently different baseline pressure and flow values, comparisons were not performed between control and chemically stiffened RBC groups. Also, data are presented in figures normalized to the mean




Fig. 1 Normalized mPAP for (a) blood replacement with chemically stiffened RBCs and (b) blood replacement with control RBCs. **P* < 0.05 versus CTL; †*P* < 0.05 versus first blood replacement.




Fig. 2 Normalized CO for (a) blood replacement with chemically stiffened RBCs and (b) blood replacement with control RBCs. **P* < 0.05 versus CTL; †*P* < 0.05 versus first blood replacement.




Fig. 3 Normalized PVR (Z_0) calculated as $mPAP/CO$ for (a) blood replacement with chemically stiffened RBCs and (b) blood replacement with control RBCs. * $P < 0.05$ versus CTL; † $P < 0.05$ versus first blood replacement.

baseline (preblood replacements) value for each condition; non-normalized data are presented in Table 1. When the ANOVA reached statistical significance, Tukey multiple comparisons were used for post hoc analysis. Data were considered significant for P -values less than 0.05. All data are presented in terms of means \pm standard error. Statistical analysis was performed using R software (Foundation for Statistical Computing, version 2.14.0).

Results

Morphometric Effects of Blood Replacement. The average body weight for the mice in each experimental group was not different (Tables 1 and 2). Hematocrit did not change significantly with blood replacement using either chemically stiffened RBCs or control RBCs (Tables 1 and 2).

Hemodynamic Effects of Blood Replacement With Chemically Treated RBCs. $mPAP$ increased significantly after the first and second blood replacements with chemically stiffened RBCs and remained elevated after the third blood replacement; $mPAP$ did not increase with blood replacement using control (untreated) RBCs (Fig. 1; Tables 1 and 2). Systolic pulmonary arterial pressure (sPAP) and diastolic pulmonary arterial pressure (dPAP) changed in the same way as $mPAP$ (Tables 1 and 2).

Cardiac output (CO) decreased continuously after the first two blood replacements of chemically stiffened RBCs and reached a plateau after the third; CO did not decrease with blood replacement using control RBCs (Fig. 2; Tables 1 and 2). Due to the increase in $mPAP$ and decrease in CO, total PVR (Z_0) increased after the first two blood replacements and reached a plateau after the third blood replacement using chemically stiffened RBCs, Z_0 did not change with blood replacement using control RBCs




Fig. 4 Normalized pulmonary arterial wave reflections (RQ) calculated as the ratio of the amplitude of backward traveling components (P_b) to forward traveling components (P_f) for (a) blood replacement with chemically stiffened RBCs and (b) blood replacement with control RBCs. * $P < 0.05$ versus CTL; † $P < 0.05$ versus first blood replacement.

(Fig. 3; Tables 1 and 2). The same pattern was evident in wave reflections (RQ) (Fig. 4; Tables 1 and 2).

Characteristic impedance (Z_C) tended to decrease with one blood replacement using chemically stiffened RBCs and significantly decreased after the second blood replacement; Z_C did not decrease with blood replacement using control RBCs (Fig. 5; Tables 1 and 2).

The duration of systole decreased with all three blood replacements using chemically stiffened RBCs; no decrease occurred with blood replacement using control RBCs (Tables 1 and 2).

PWV, pulmonary arterial compliance, systemic systolic pressure, main pulmonary artery diameter, and pulse pressure did not change after any blood replacement using either chemically stiffened RBCs or control RBCs (Tables 1 and 2). Heart rate did not change after any infusion of chemically stiffened RBCs and did not decrease after the first or third infusion of control RBCs; however, it did significantly decrease after the second infusion of control RBCs (Tables 1 and 2).

Blood viscosity was not changed after three blood replacements with chemically stiffened RBCs compared to whole blood from donors (Fig. 6).

Discussion

The major, novel contribution of this study is demonstrating that RBC stiffening plays a key role in altering pulmonary vascular hemodynamics and increasing RV afterload, including increasing $mPAP$, PVR, and wave reflections.

SCD is known to cause increased RBC stiffness [22,23] through mechanisms that remain poorly understood but likely involve abnormal RBC membrane properties, abnormal intracellular




Fig. 5 Normalized characteristic impedance (Z_c) calculated from dP/dQ when flow reaches 95% of its maximal value for (a) blood replacement with chemically stiffened RBCs and (b) blood replacement with control RBCs. * $P < 0.05$ versus CTL; † $P < 0.05$ versus first blood replacement.

hemoglobin polymerization, and increased intracellular density. While the impact of each of these RBC abnormalities on blood flow has been tested in vitro [24–28], no studies to date have investigated their physiological impact. Here, we investigated how RBC stiffening acutely affects pulmonary pulsatile hemodynamics for the first time in vivo. Furthermore, while SCD often affects both RBC mechanics and morphology [29], there is a separate class of RBCs in SCD with altered mechanics but apparently normal morphology [30]. Hence, our results obtained with glutaraldehyde-treated RBCs that have increased stiffness and unchanged morphology [19] are especially relevant to the clinical impact of these SCD RBCs in SCD.

To isolate how changes in RBC stiffness affect the pulmonary vasculature, we replaced 50 μ l of whole blood with 50 μ l of a solution containing chemically stiffened RBCs (45% by volume, or 45% Hct) three separate times. We demonstrate for the first time that stiffened RBCs increase the static component of RV afterload, PVR, continuously, evidenced by both continual increases in mPAP and continual decreases in cardiac output.

We also demonstrate for the first time that stiffened RBCs alter the pulsatile component of RV afterload. Stiffened RBCs acutely increased wave reflections, which is suggestive of increased arterial stiffening. The increase in mPAP could be a possible explanation for acutely increased pulmonary arterial stiffness due to strain-induced arterial stiffening [31]. Additionally, increased backward wave reflection traveling to the heart (RQ; Fig. 4) could be caused by trapping of the stiffened RBCs in the lung capillaries. We also found that stiffened RBCs altered the pressure waveform such that the duration of systole was shorter, which may have been caused by increased wave reflections. This finding also suggests that the right ventricle was not able to fully compensate




Fig. 6 Shear stress versus shear rate for donor whole blood (donor) and whole blood from mice after three blood replacements with chemically stiffened RBCs (Stiff RBC replacement) obtained using an oscillatory tube viscometer. * $P < 0.05$ versus CTL.

for the effects of chemically stiffened RBCs. However, we did not measure RV function in this study.

We observed a statistically significant decrease in Z_c , which would suggest decreased, not increased, pulmonary arterial stiffening. However, as discussed in Ref. [20], Z_c depends not only on proximal artery stiffness (with an inverse square root relationship) but also on blood inertance in the proximal arteries (with a square root relationship). The decrease in CO found here decreases inertance, which likely explains the decrease in Z_c . Viscous losses along the artery walls and Womersley's number can also affect the longitudinal impedance Z_L [32,33], which contributes to the characteristic impedance, but neither viscosity nor heart rate (or PA diameter) changed with stiffened RBCs. We did not observe significant differences in PWV or pulmonary arterial compliance with stiffened RBCs, but both tended to decrease following the same pattern as Z_c .

Hematocrit did not change after infusions of stiffened or control RBCs, which was expected given our experimental design. Whole blood viscosity also did not change after three infusions of stiffened RBCs at any shear rate measured. This finding is likely due to the relatively small amount of stiffened RBCs infused. If we assume that the total blood volume of a mouse is 1.8 ml [34] and Hct is 45%, then the replacement of $\sim 67.5 \mu$ l normal RBCs (i.e., 150 μ l whole blood at 45% RBCs by volume) with $\sim 67.5 \mu$ l stiffened RBCs leads to blood with at most 8.3% of the RBCs in the blood stiffened. Furthermore, stiffened RBCs are more likely to be trapped in both the pulmonary and systemic microcirculation, and therefore may be underrepresented in our samples. That said, even in SCD patients, viscosity of whole blood can be normal when tested ex vivo in a fully oxygenated state [35]. We did not measure the viscosity of a solution of 100% stiffened RBCs. A benefit of the constancy of both hematocrit and whole blood viscosity with our blood replacements is that it does not confound the interpretation of results. That is, the significant increases in mPAP, PVR, and wave reflections found here must be due to the increased RBC stiffness, as opposed to how changes in RBC stiffness alter viscosity and thereby alter pulmonary pulsatile hemodynamics.

There are four main limitations of this work. First, we did not measure the stiffness of our glutaraldehyde-stiffened RBCs. Sickled RBCs, when tested with micropipette aspiration, have an elastic shear modulus of $21.1 \times 10^{-3} \mu$ dyn/cm, compared to normal RBCs, which have an elastic shear modulus of $11.0 \times 10^{-3} \mu$ dyn/cm [36]. Exposure of normal RBCs to 0.010% and 0.019% glutaraldehyde solution for 1 hr results in RBCs having an elastic shear moduli $22.0 \times 10^{-2} \mu$ dyn/cm and

$32.0 \times 10^{-2} \mu\text{dyn/cm}$, respectively [37], which are an order of magnitude larger than both sickled and normal RBC moduli. We exposed to normal RBCs to 0.016% glutaraldehyde for 30 min, which should cause less stiffening, but we cannot directly relate our treatment to the clinical disease state in the absence of direct measurements. Second, glutaraldehyde-stiffened RBCs may deliver less oxygen than untreated, control RBCs, which could cause vasoconstriction and subsequent increases in total PVR independent of RBC stiffening. Previous literature has shown that glutaraldehyde-fixed hemoglobin has a saturation curve with P50 at 20 mmHg, close to the normal hemoglobin value of 26.6 mmHg and far from the myoglobin value of 2.8 mmHg [38], so we anticipate this potential effect is small. Third, glutaraldehyde-treated RBCs are potentially cytotoxic, which could increase PVR due to platelet activation, injury-induced vasoconstriction, and inflammation. Previous literature has reported that washing glutaraldehyde-treated RBCs three times over 2 hrs removes all traces of glutaraldehyde from solution [39], so that upon blood replacement free glutaraldehyde in solution does not initiate a clotting cascade. To be conservative, we chose eight washes over 3 hrs to minimize this potential effect. Fourth, two different small animal surgeons performed the in vivo measurements and obtained different baseline pressure and flow values, which precluded a quantitative comparison of PVZ metrics between control and stiffened RBC groups. The absence of changes in PVZ metrics with multiple blood replacements using control RBCs gives us confidence in our interpretation of results despite this limitation.

The major novel finding of this study is that chemically stiffened RBCs affect both static and dynamic components of RV afterload. The effects of other SCD-related RBC changes on pulmonary vascular hemodynamics and RV function merit further investigation.

Acknowledgment

We thank Dr. Ron R. Magness for the use of his viscometer. We would also like to thank Gouqing Song and Gaoussou Diarra for their surgical expertise performing the in vivo hemodynamic measurements. This study was supported by National Institutes of Health (NIH), NIH R01-HL086939 (NCC), NIH F31 HL128088-01 (DAS), NIH HL49210 (RRM), HD38843 (RRM), and by HL117341 (RRM).

References

- [1] World Health Organization, 2006, "Sickle-Cell Anaemia: Report by the Secretariat," 59th World Health Assembly, Geneva, Switzerland, May 22–27. Report No. EB117/R3.
- [2] Bunn, H. F., 1997, "Pathogenesis and Treatment of Sickle Cell Disease," *N. Engl. J. Med.*, **337**(11), pp. 762–769.
- [3] Stuart, M. J., and Nagel, R. L., 2004, "Sickle-Cell Disease," *Lancet*, **364**(9442), pp. 1343–1360.
- [4] Machado, R. F., and Farber, H. W., 2013, "Pulmonary Hypertension Associated With Chronic Hemolytic Anemia and Other Blood Disorders," *Clin. Chest Med.*, **34**(4), pp. 739–752.
- [5] Bunn, H. F., Nathan, D. G., Dover, G. J., Hebbel, R. P., Platt, O. S., Rosse, W. F., and Ware, R. E., 2010, "Pulmonary Hypertension and Nitric Oxide Depletion in Sickle Cell Disease," *Blood*, **116**(5), pp. 687–692.
- [6] Maciaszek, J. L., Andemariam, B., and Lykotrafitis, G., 2011, "Microelasticity of Red Blood Cells in Sickle Cell Disease," *J. Strain Anal. Eng.*, **46**(5), pp. 368–379.
- [7] Aessopos, A., Farmakis, D., Tsironi, M., Diamanti-Kandarakis, E., Matzourani, M., Fragodimiri, C., Hatziliami, A., and Karagiorga, M., 2007, "Endothelial Function and Arterial Stiffness in Sickle-Thalassemia Patients," *Atherosclerosis*, **191**(2), pp. 427–432.
- [8] Castro, O., Hoque, M., and Brown, B. D., 2003, "Pulmonary Hypertension in Sickle Cell Disease: Cardiac Catheterization Results and Survival," *Blood*, **101**(4), pp. 1257–1261.
- [9] Charache, S., 1994, "Sickle Cells and Sudden Death," *J. Lab. Clin. Med.*, **124**(4), pp. 473–474.
- [10] Ataga, K. I., Sood, N., De Gent, G., Kelly, E., Henderson, A. G., Jones, S., Strayhorn, D., Lail, A., Lief, S., and Orringer, E. P., 2004, "Pulmonary Hypertension in Sickle Cell Disease," *Am. J. Med.*, **117**(9), pp. 665–669.
- [11] De Castro, L. M., Jonassaint, J. C., Graham, F. L., Ashley-Koch, A., and Telen, M. J., 2008, "Pulmonary Hypertension Associated With Sickle Cell Disease: Clinical and Laboratory Endpoints and Disease Outcomes," *Am. J. Hematol.*, **83**(1), pp. 19–25.
- [12] Haque, A. K., Gokhale, S., Rampy, B. A., Adegboyega, P., Duarte, A., and Saldana, M. J., 2002, "Pulmonary Hypertension in Sickle Cell Hemoglobinopathy: A Clinicopathologic Study of 20 Cases," *Hum. Pathol.*, **33**(10), pp. 1037–1043.
- [13] Fonseca, G. H., Souza, R., Salemi, V. M., Jardim, C. V., and Gualandro, S. F., 2012, "Pulmonary Hypertension Diagnosed by Right Heart Catheterisation in Sickle Cell Disease," *Eur. Respir. J.*, **39**(1), pp. 112–118.
- [14] Barst, R. J., Mubarak, K. K., Machado, R. F., Ataga, K. I., Benza, R. L., Castro, O., Naeije, R., Sood, N., Swerdlow, P. S., Hildesheim, M., Gladwin, M. T., and ASSET Study Group, 2010, "Exercise Capacity and Haemodynamics in Patients With Sickle Cell Disease With Pulmonary Hypertension Treated With Bosentan: Results of the ASSET Studies," *Br. J. Haematol.*, **149**(3), pp. 426–435.
- [15] Machado, R. F., Barst, R. J., Yovetich, N. A., Hassell, K. L., Kato, G. J., Gordeuk, V. R., Gibbs, J. S., Little, J. A., Schraufnagel, D. E., Krishnamurti, L., Girgis, R. E., Morris, C. R., Rosenzweig, E. B., Badesch, D. B., Lanzkron, S., Onyekwere, O., Castro, O. L., Sachdev, V., Waclawiw, M. A., Woolson, R., Goldsmith, J. C., Gladwin, M. T., and Walk-PHaSST Investigators and Patients, 2011, "Hospitalization for Pain in Patients With Sickle Cell Disease Treated With Sildenafil for Elevated TRV and Low Exercise Capacity," *Blood*, **118**(4), pp. 855–864.
- [16] Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landberg, M., Machado, R. F., Olschewski, H., Robbins, I. M., and Souza, R., 2013, "Updated Clinical Classification of Pulmonary Hypertension," *J. Am. Coll. Cardiol.*, **62**(25 Suppl), pp. D34–D41.
- [17] Forsyth, A. M., Wan, J., Ristenpart, W. D., and Stone, H. A., 2010, "The Dynamic Behavior of Chemically 'Stiffened' Red Blood Cells in Microchannel Flows," *Microvasc. Res.*, **80**(1), pp. 37–43.
- [18] Mokken, F. C., Kedaria, M., Henny, C. P., Hardeman, M. R., and Gelb, A. W., 1992, "The Clinical Importance of Erythrocyte Deformability, a Hemorrheological Parameter," *Ann. Hematol.*, **64**(3), pp. 113–122.
- [19] Morel, F. M., Baker, R. F., and Wayland, H., 1971, "Quantitation of Human Red Blood Cell Fixation by Glutaraldehyde," *J. Cell Biol.*, **48**(1), pp. 91–100.
- [20] Schreier, D. A., Hacker, T. A., Hunter, K. S., Eickoff, J., Liu, A., Song, G., and Chesler, N. C., 2014, "The Impact of Increased Hematocrit on Right Ventricular Afterload in Response to Chronic Hypoxia," *J. Appl. Physiol.*, **117**(8), pp. 833–839.
- [21] Tabima, D. M., Roldan-Alzate, A., Wang, Z., Hacker, T. A., Molthen, R. C., and Chesler, N. C., 2012, "Persistent Vascular Collagen Accumulation Alters Hemodynamic Recovery From Chronic Hypoxia," *J. Biomech.*, **45**(5), pp. 799–804.
- [22] Brandao, M. M., Fontes, A., Barjas-Castro, M. L., Barbosa, L. C., Costa, F. F., Cesar, C. L., and Saad, S. T., 2003, "Optical Tweezers for Measuring Red Blood Cell Elasticity: Application to the Study of Drug Response in Sickle Cell Disease," *Eur. J. Haematol.*, **70**(4), pp. 207–211.
- [23] Higgins, J. M., Eddington, D. T., Bhatia, S. N., and Mahadevan, L., 2007, "Sickle Cell Vasooclusion and Rescue in a Microfluidic Device," *Proc. Natl. Acad. Sci. U.S.A.*, **104**(51), pp. 20496–20500.
- [24] Ballas, S. K., and Mohandas, N., 2004, "Sickle Red Cell Microrheology and Sickle Blood Rheology," *Microcirculation*, **11**(2), pp. 209–225.
- [25] Eaton, W. A., and Hofrichter, J., 1990, "Sickle Cell Hemoglobin Polymerization," *Adv. Protein Chem.*, **40**, pp. 63–279.
- [26] Hiruma, H., Noguchi, C. T., Uyesaka, N., Schechter, A. N., and Rodgers, G. P., 1995, "Contributions of Sickle Hemoglobin Polymer and Sickle Cell Membranes to Impaired Filterability," *Am. J. Physiol.*, **268**(5), pp. H2003–H2008.
- [27] Noguchi, C. T., Torchia, D. A., and Schechter, A. N., 1980, "Determination of Deoxyhemoglobin S Polymer in Sickle Erythrocytes Upon Deoxygenation," *Proc. Natl. Acad. Sci. U.S.A.*, **77**(9), pp. 5487–5491.
- [28] Wood, D. K., Soriano, A., Mahadevan, L., Higgins, J. M., and Bhatia, S. N., 2012, "A Biophysical Indicator of Vaso-Occlusive Risk in Sickle Cell Disease," *Sci. Transl. Med.*, **4**(123), p. 123ra126.
- [29] Barabino, G. A., Platt, M. O., and Kaul, D. K., 2010, "Sickle Cell Biomechanics," *Annu. Rev. Biomed. Eng.*, **12**(1), pp. 345–367.
- [30] Shaked, N. T., Satterwhite, L. L., Telen, M. J., Truskey, G. A., and Wax, A., 2011, "Quantitative Microscopy and Nanoscopy of Sickle Red Blood Cells Performed by Wide Field Digital Interferometry," *J. Biomed. Opt.*, **16**(3), p. 030506.
- [31] Bellofiore, A., Roldan-Alzate, A., Besse, M., Kelliham, H. B., Consigny, D. W., Francois, C. J., and Chesler, N. C., 2013, "Impact of Acute Pulmonary Embolization on Arterial Stiffening and Right Ventricular Function in Dogs," *Ann. Biomed. Eng.*, **41**(1), pp. 195–204.
- [32] Milnor, W. R., 1982, *Hemodynamics*, Williams and Wilkins, Baltimore, MD.
- [33] Womersley, J. R., 1957, "The Mathematical Analysis of the Arterial Circulation in a State of Oscillatory Motion," Wright Air Development Center, Wright Patterson Air Force Base, OH, Technical Report No. WADC-TR 56-614.
- [34] Diehl, K. H., Hull, R., Morton, D., Pfister, R., Rabemampianina, Y., Smith, D., Vidal, J. M., van de Vorstenbosch, C., European Federation of Pharmaceutical Industries Association, and European Centre for the Validation of Alternative Methods, 2001, "A Good Practice Guide to the Administration of Substances and Removal of Blood, Including Routes and Volumes," *J. Appl. Toxicol.*, **21**(1), pp. 15–23.

- [35] Thurston, G. B., Henderson, N. M., and Jeng, M., 2004, "Effects of Erythrocytapheresis Transfusion on the Viscoelasticity of Sickle Cell Blood," *Clin. Hemorheol. Microcirc.*, **30**(2), pp. 83–97.
- [36] Athanassiou, G., Moutzouri, A., Kourakli, A., and Zoumbos, N., 2006, "Effect of Hydroxyurea on the Deformability of the Red Blood Cell Membrane in Patients With Sickle Cell Anemia," *Clin. Hemorheol. Microcirc.*, **35**(1–2), pp. 291–295.
- [37] Bessis, M., Shohet, S. B., and Mohandas, N., 1978, *Red Cell Rheology*, Springer, Berlin, pp. 178–179.
- [38] Eike, J. H., and Palmer, A. F., 2004, "Effect of Glutaraldehyde Concentration on the Physical Properties of Polymerized Hemoglobin-Based Oxygen Carriers," *Biotechnol. Prog.*, **20**(4), pp. 1225–1232.
- [39] Bozzola, J. J., and Russell, L. D., 1999, *Electron Microscopy: Principles and Techniques for Biologists*, Jones & Bartlett Learning, Burlington, MA.